focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCOS.L Regulatory News (COS)

  • There is currently no data for COS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Jellagen Collaboration

17 Oct 2014 07:00

RNS Number : 5369U
Collagen Solutions PLC
17 October 2014
 

Collagen Solutions Plc

(the "Company" or the "Group")

 

Funded Research Collaboration with Jellagen

Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces that it will be collaborating with Jellagen Pty Ltd ('Jellagen') as part of a Small firms' Merit Award for Research and Technology ('SMART') grant to improve the production of medical grade collagen derived from jellyfish.

 

The SMART funding from Innovate UK amounts to almost £100k and will help Jellagen improve their product quality as well as the efficiency of collagen extraction from jellyfish. This funding will also be used to investigate, alongside Collagen Solutions, Swansea University's Centre for Nano Health and University College London ('UCL'), the utilisation of jellyfish derived, medical grade, Type II and Type V collagen for the fabrication of various medical devices. This will include the generation of specific biological data on the use of this improved collagen for applications in bone grafts

 

Stewart White, CEO of Collagen Solutions commented: "We require access to consistent supplies of medical grade collagen derived from jellyfish and therefore made a strategic investment in Jellagen when it was founded. We see this as a reliable and renewable source of novel medical grade collagen which we can then help to fabricate into potential medical products. This development work will be carried out with the support of our in-house teams in San Diego and Glasgow. The SMART funding will allow Collagen Solutions to provide further support in order to develop novel commercial forms of Jellyfish collagen for Jellagen."

 

 

Enquiries:

 

Collagen Solutions Plc

 

David Evans, Chairman 

Tel: 07740 084 452

Stewart White, CEO

Tel: 0141 558 2008

 

 

Zeus Capital (Nominated Adviser and Broker)

 

Ross Andrews / John Depasquale (Corporate Finance)

Tel: 0161 831 1512

Dominic Wilson (Institutional Sales)

Tel: 020 7533 7727

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 or collagen@walbrookpr.com

Mike Wort

Mob: 07900 608 002

Anna Dunphy

Mob: 07876 741 001

 

 

Notes to Editors:

About Jellagen:

Jellagen was founded in May 2013 and offers the full spectrum of jellyfish derived collagen proteins being the first provider of pharma grade, GMP, and ISO certified Type II and Type V jellyfish collagen. This collagen is a raw material for fabrication into devices for regenerative medicine and the cell culture market.

Collagen is used in the manufacture of biomaterials due to its ability to form strong fibres and is used in many forms (such as gels, scaffolds and membranes) for a number of medical applications ranging from wound care and cartilage repair through to bone grafts.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAGGGWAUUPCGCQ
Date   Source Headline
20th Feb 20197:00 amRNSSale of Strategic Investment in Jellagen
18th Feb 20197:00 amRNSPresenting at the Hardman Investor Forum
4th Feb 20193:55 pmRNSVisit from Member of Scottish Parliament
31st Jan 20197:00 amRNSChondroMimetic® Update
16th Jan 20194:52 pmRNSDirector/PDMR Shareholding
15th Jan 20197:00 amRNSNew Manufacturing Agreement
7th Jan 20193:45 pmRNSAward of £1.54 million Scottish Enterprise Grant
4th Dec 20187:00 amRNSHalf-year Report
7th Nov 20187:00 amRNSInvestor presentation
5th Nov 20187:00 amRNSRealignment of Bond Repayments
23rd Oct 20187:00 amRNSTrading Update and Notice of Results
18th Oct 20187:00 amRNSBiotech and Money's Inve$tival Showcase
26th Sep 20185:04 pmRNSHolding(s) in Company
25th Sep 20183:05 pmRNSDirector/PDMR Shareholding
19th Sep 20185:01 pmRNSDirector/PDMR Shareholding
3rd Sep 201812:20 pmRNSDirector/PDMR Shareholding
3rd Sep 20187:00 amRNSBoard Appointments
3rd Sep 20187:00 amRNSExecutive Share Options Alignment
24th Aug 201811:47 amRNSDirector/PDMR Shareholding
22nd Aug 201811:40 amRNSResult of AGM
22nd Aug 20187:00 amRNSAGM Statement
21st Aug 20187:00 amRNSAppointment of Distributors in China
25th Jul 20185:21 pmRNSPosting of Annual Report and Notice of AGM
10th Jul 20187:00 amRNSFinal Results
13th Jun 20187:00 amRNSNotice of Results
8th May 20187:00 amRNSExhibiting at 18th ESSKA conference
3rd May 20183:27 pmRNSDirector/PDMR Shareholding
11th Apr 20187:00 amRNSDirector/PDMR Shareholding
10th Apr 20187:00 amRNSAppointment of Chief Business Officer
6th Apr 20189:31 amRNSDirector/PDMR Shareholding
4th Apr 20187:00 amRNSTrading update
28th Mar 20187:00 amRNSProposed restructuring of New Zealand operations
1st Mar 20187:00 amRNSConference attendance
26th Feb 20187:15 amRNSHardman & Co: Nearing first proprietary product
22nd Feb 20181:00 pmRNSDirector/PDMR Shareholding
21st Feb 20187:00 amRNSPositive results of ChondroMimetic Clinical Study
15th Feb 20187:00 amRNSChina update
6th Feb 20187:00 amRNSInvestor presentation
20th Dec 201711:55 amRNSChondroMimetic® Update
19th Dec 20173:49 pmRNSHardman Research: Targeting long-term growth
18th Dec 20177:00 amRNSDirectorate Change
14th Dec 20177:00 amRNSAppointment of Chief Financial Officer
5th Dec 20177:00 amRNSHalf-year Report
27th Nov 20174:41 pmRNSSecond Price Monitoring Extn
27th Nov 20174:35 pmRNSPrice Monitoring Extension
26th Oct 20177:00 amRNSTrading update and notice of results
21st Sep 20171:28 pmRNSHardman Research: Engineering towards CE Mark
21st Sep 20177:00 amRNSStudy Update Patient Assessments Completed
18th Sep 20177:00 amRNSPresenting at the Hardman Investor Forum
12th Sep 20177:00 amRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.